Biomarkers and Surrogate Endpoints in Drug Development: A European Regulatory View.

Purpose To give a European regulatory overview of the requirements on and the use of biomarkers or surrogate endpoints in the development of drugs for ocular disease. Methods Definitions, methods to validate new markers, and circumstances where surrogate endpoints can be appropriate are summarized. Results The key endpoints that have been used in… CONTINUE READING

1 Figure or Table